cerca CERCA
Sabato 27 Febbraio 2021
Aggiornato: 21:55
Temi caldi


WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer

SHANGHAI and WUPPERTAL, Germany, Dec. 21, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Bayer, today announced an acquisition deal, under which WuXi Biologics will take over and operate the Drug Substance (DS) facility at Bayer's Wuppertal site. The companies also plan to enter into a long-term sublease agreement and a transition service contract. The volume of the transaction, including the sublease agree...

Gunvor Closes Innovative New EUR 300 Mil. Natural Gas Facility

GENEVA, Dec. 21, 2020 /PRNewswire/ -- Gunvor Group ("Gunvor" or "the Company") has successfully closed a new EUR 300 million financing (the "Facility"), which consists of a syndicated, pan-European natural gas repo facility to cover multiple jurisdictions in Europe with a shared security package. It will be used to support Gunvor's growing natural gas activity across Europe, where the company is already one of the largest physical natural gas traders.

Hydro-Québec to operate one of the world's most powerful electrolyzers to produce green hydrogen

MONTRÉAL, Dec. 8, 2020 /PRNewswire/ -- Hydro-Québec is announcing the construction of an electrolyzer facility with a capacity of about 90 MW, making it one of the most powerful electrolyzers in the world to produce green hydrogen. The facility will supply green hydrogen and oxygen to the Recyclage Carbone Varennes (RCV) plant project, which will transform non-recyclable waste into biofuels, providing an alternative to landfill.

AGC Biologics Shifts Leadership Structure at United States and Copenhagen Sites to Support the Continued Development and Growth of the Regions

SEATTLE, Oct. 15, 2020 /PRNewswire/ -- AGC Biologics, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), has announced a leadership update at the United States and Copenhagen facilities. The changes are being made to strengthen the strategic development and executive oversight of the rapid growing facilities in the US and Copenhagen, and are effective at the date of release, October 15, 2020.

Sai Life Sciences expands suite of cellular analysis platforms in Cambridge, MA

CAMBRIDGE, Mass. and HYDERABAD, India, Sept. 10, 2020 /PRNewswire/ --  Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the addition of state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA. 

ora in
Prima pagina
in Evidenza